Investment Rating - The report does not explicitly state an investment rating for Duality Biologics (9606 HK) Core Insights - At the 2026 ASCO Genitourinary Cancers Symposium, Duality Biologics presented promising efficacy and safety data for its drug DB1311/BNT324 (B7H3 ADC) in treating late-line castration-resistant prostate cancer (CRPC) [1][6] - The data from the Phase I/II clinical trial included 104 treated patients, with a median of 4 prior lines of therapy [1][6] - As of September 5, 2025, the median follow-up was 9.2 months, with 52 patients still on treatment [2][7] - Among 58 evaluable patients, the PSA50 response rate was 35.4%, with a confirmed overall response rate (ORR) of 34.5% and a disease control rate (DCR) of 87.9% [2][7] - The median duration of response (DOR) was 10.2 months, and the median radiographic progression-free survival (rPFS) was 11.3 months [2][7] - The safety profile was consistent with previous reports, primarily consisting of Grade 1-2 adverse events [2][7] Summary by Sections Efficacy Data - The report highlights that the rPFS rate improved from 61% to 72% with an expanded sample size and extended follow-up [3][9] - The efficacy in patients who had previously received Lu177 treatment was also notable, with a PSA50 response rate of 30.4% and a DCR of 100% [8] Comparative Analysis - The rPFS rate of DB1311 compares favorably against other treatments, such as Novartis' Lu177 and Johnson & Johnson's KLK2*CD3 TCE, indicating its potential as a best-in-class therapy [3][9]
映恩生物-B（09606）：核心产品B7H3ADC前列腺癌数据披露，PFS数据优异